AR126464A1 - Agentes para el tratamiento de cánceres positivos para cldn6 - Google Patents
Agentes para el tratamiento de cánceres positivos para cldn6Info
- Publication number
- AR126464A1 AR126464A1 ARP220101862A ARP220101862A AR126464A1 AR 126464 A1 AR126464 A1 AR 126464A1 AR P220101862 A ARP220101862 A AR P220101862A AR P220101862 A ARP220101862 A AR P220101862A AR 126464 A1 AR126464 A1 AR 126464A1
- Authority
- AR
- Argentina
- Prior art keywords
- cldn6
- immunoglobulin
- specificity
- derived
- amino acid
- Prior art date
Links
- 102100038449 Claudin-6 Human genes 0.000 title abstract 11
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 title abstract 11
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000018358 immunoglobulin Human genes 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000011230 binding agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención generalmente se refiere a agentes de unión que son al menos biespecíficos para la unión a CD3 y CLDN6, es decir, son capaces de unirse a al menos CD3 y CLDN6. Específicamente, la presente invención se refiere al RNA que codifica estos agentes de unión que pueden usarse en el tratamiento o la prevención del cáncer en un sujeto. Reivindicación 1: Una composición o preparación médica caracterizada porque comprende: (I) un primer RNA que codifica una primera cadena polipeptídica que comprende una región variable de una cadena pesada (VH) derivada de una inmunoglobulina con especificidad para CD3 (VH(CD3)), una región variable de una cadena pesada (VH) derivada de una inmunoglobulina con especificidad para CLDN6 (VH(CLDN6)) y una región variable de una cadena ligera (VL) derivada de una inmunoglobulina con especificidad para CLDN6 (VL(CLDN6)); y (II) un segundo RNA que codifica una segunda cadena polipeptídica que comprende una región variable de una cadena ligera (VL) derivada de una inmunoglobulina con especificidad para CD3 (VL(CD3)), una región variable de una cadena pesada (VH) derivada de una inmunoglobulina con especificidad para CLDN6 (VH(CLDN6)) y una región variable de una cadena ligera (VL) derivada de una inmunoglobulina con especificidad para CLDN6 (VL(CLDN6)). Reivindicación 43: Una composición o preparación médica caracterizada porque comprende: (I) un primer RNA que codifica una primera cadena polipeptídica que comprende la secuencia de aminoácidos de la SEQ ID Nº 4, o una secuencia de aminoácidos que tiene por lo menos un 99%, un 98%, un 97%, un 96%, un 95%, un 90%, un 85% o un 80% de identidad con respecto a la secuencia de aminoácidos de la SEQ ID Nº 4; y (II) un segundo RNA que codifica una segunda cadena polipeptídica que comprende la secuencia de aminoácidos de la SEQ ID Nº 6, o una secuencia de aminoácidos que tiene por lo menos un 99%, un 98%, un 97%, un 96%, un 95%, un 90%, un 85% o un 80% de identidad con respecto a la secuencia de aminoácidos de la SEQ ID Nº 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021069869 | 2021-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126464A1 true AR126464A1 (es) | 2023-10-11 |
Family
ID=82781147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101862A AR126464A1 (es) | 2021-07-15 | 2022-07-15 | Agentes para el tratamiento de cánceres positivos para cldn6 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250009780A1 (es) |
| EP (1) | EP4370551A1 (es) |
| JP (1) | JP2024525795A (es) |
| KR (1) | KR20240035794A (es) |
| CN (1) | CN117642429A (es) |
| AR (1) | AR126464A1 (es) |
| AU (1) | AU2022311053A1 (es) |
| CA (1) | CA3226700A1 (es) |
| IL (1) | IL309495A (es) |
| MX (1) | MX2024000678A (es) |
| TW (1) | TW202327647A (es) |
| WO (1) | WO2023285560A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY40490A (es) | 2022-10-17 | 2024-04-30 | Pfizer | Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos |
| WO2025179238A2 (en) | 2024-02-23 | 2025-08-28 | BioNTech SE | Coronavirus vaccine |
| WO2025230946A1 (en) * | 2024-04-30 | 2025-11-06 | Modernatx, Inc. | T cell engagers and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2920209B1 (en) * | 2012-11-13 | 2020-08-05 | BioNTech SE | Agents for treatment of claudin expressing cancer diseases |
| CN105073776B (zh) * | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| EP4212510A1 (en) | 2015-10-28 | 2023-07-19 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| WO2020191344A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
-
2022
- 2022-07-13 CN CN202280046768.5A patent/CN117642429A/zh active Pending
- 2022-07-13 TW TW111126241A patent/TW202327647A/zh unknown
- 2022-07-13 IL IL309495A patent/IL309495A/en unknown
- 2022-07-13 CA CA3226700A patent/CA3226700A1/en active Pending
- 2022-07-13 MX MX2024000678A patent/MX2024000678A/es unknown
- 2022-07-13 US US18/578,844 patent/US20250009780A1/en active Pending
- 2022-07-13 WO PCT/EP2022/069659 patent/WO2023285560A1/en not_active Ceased
- 2022-07-13 JP JP2024502029A patent/JP2024525795A/ja active Pending
- 2022-07-13 EP EP22750715.9A patent/EP4370551A1/en active Pending
- 2022-07-13 KR KR1020247001508A patent/KR20240035794A/ko active Pending
- 2022-07-13 AU AU2022311053A patent/AU2022311053A1/en active Pending
- 2022-07-15 AR ARP220101862A patent/AR126464A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117642429A (zh) | 2024-03-01 |
| AU2022311053A1 (en) | 2023-12-14 |
| KR20240035794A (ko) | 2024-03-18 |
| IL309495A (en) | 2024-02-01 |
| TW202327647A (zh) | 2023-07-16 |
| EP4370551A1 (en) | 2024-05-22 |
| MX2024000678A (es) | 2024-02-07 |
| CA3226700A1 (en) | 2023-01-19 |
| WO2023285560A1 (en) | 2023-01-19 |
| US20250009780A1 (en) | 2025-01-09 |
| AU2022311053A9 (en) | 2024-01-04 |
| JP2024525795A (ja) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126464A1 (es) | Agentes para el tratamiento de cánceres positivos para cldn6 | |
| WO2022204316A3 (en) | Variant nucleic acid libraries for cd3 | |
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| AR126154A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| PE20220505A1 (es) | Moleculas de union a tigit y pd-1/tigit | |
| BR112021014255A2 (pt) | Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| AR080663A1 (es) | Proteinas de union especificas y sus usos | |
| ZA202400787B (en) | Pharmaceutical composition and use | |
| CU20230010A7 (es) | Neoantígenos ras | |
| PE20230385A1 (es) | Anticuerpos anti-phf-tau y usos de estos | |
| AR128689A1 (es) | Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos | |
| ZA202403275B (en) | Anti-lag3 antibody, pharmaceutical composition and use | |
| MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
| WO2021252620A3 (en) | Dna encoded antibodies for use against sars-cov-2 | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR130991A2 (es) | PROTEÍNAS DE UNIÓN A TGF-b-RII | |
| MX2023015244A (es) | Anticuerpos biespecificos y usos de los mismos. | |
| RU2011104709A (ru) | Фармацевтическая композиция для лечения и предупреждения рака |